Cargando…
Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer
The effect of chemotherapy on programmed cell death-ligand 1 (PD-L1) expression has been previously studied in lung cancer, while the results remain controversial. The aim of this study was to investigate the variation of PD-L1 expression after neoadjuvant chemotherapy and explore the association be...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587215/ https://www.ncbi.nlm.nih.gov/pubmed/31145232 http://dx.doi.org/10.1097/CJI.0000000000000275 |
_version_ | 1783429021764157440 |
---|---|
author | Guo, Lei Song, Peng Xue, Xuemin Guo, Changyuan Han, Liankui Fang, Qing Ying, Jianming Gao, Shugeng Li, Wenbin |
author_facet | Guo, Lei Song, Peng Xue, Xuemin Guo, Changyuan Han, Liankui Fang, Qing Ying, Jianming Gao, Shugeng Li, Wenbin |
author_sort | Guo, Lei |
collection | PubMed |
description | The effect of chemotherapy on programmed cell death-ligand 1 (PD-L1) expression has been previously studied in lung cancer, while the results remain controversial. The aim of this study was to investigate the variation of PD-L1 expression after neoadjuvant chemotherapy and explore the association between chemotherapy response, prognosis and the variation of PD-L1 expression in lung cancer patients. A total of 63 lung cancer patients who received platinum-based neoadjuvant chemotherapy and subsequently underwent surgical resection were selected. PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC) was assessed by immunohistochemistry using 22C3 monoclonal antibody in these 63 matched lung cancer specimens before and after neoadjuvant chemotherapy. The positivity of PD-L1 on TC changed from 17.5% to 39.7% after neoadjuvant chemotherapy and the positivity of PD-L1 on IC changed from 19.0% to 71.4% after neoadjuvant chemotherapy. The elevation of PD-L1 expression on TC after neoadjuvant chemotherapy was more frequently observed in patients achieving stable disease or progressive disease than in patients achieving partial response (P=0.026). Patients with elevated PD-L1 expression on TC after neoadjuvant chemotherapy showed a trend to have a shorter progression-free survival than patients without elevated PD-L1 expression on TC, although the difference was not statistically significant in multivariate analysis (hazard ratio=2.38, 95% confidence interval=0.99–5.73, P=0.053). PD-L1 expression can be elevated by chemotherapy in lung cancer. Furthermore, elevation of PD-L1 expression on TC after neoadjuvant chemotherapy was associated with reduced chemotherapy response and inferior progression-free survival in patients with lung cancer. |
format | Online Article Text |
id | pubmed-6587215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-65872152019-07-22 Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer Guo, Lei Song, Peng Xue, Xuemin Guo, Changyuan Han, Liankui Fang, Qing Ying, Jianming Gao, Shugeng Li, Wenbin J Immunother Clinical Studies The effect of chemotherapy on programmed cell death-ligand 1 (PD-L1) expression has been previously studied in lung cancer, while the results remain controversial. The aim of this study was to investigate the variation of PD-L1 expression after neoadjuvant chemotherapy and explore the association between chemotherapy response, prognosis and the variation of PD-L1 expression in lung cancer patients. A total of 63 lung cancer patients who received platinum-based neoadjuvant chemotherapy and subsequently underwent surgical resection were selected. PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC) was assessed by immunohistochemistry using 22C3 monoclonal antibody in these 63 matched lung cancer specimens before and after neoadjuvant chemotherapy. The positivity of PD-L1 on TC changed from 17.5% to 39.7% after neoadjuvant chemotherapy and the positivity of PD-L1 on IC changed from 19.0% to 71.4% after neoadjuvant chemotherapy. The elevation of PD-L1 expression on TC after neoadjuvant chemotherapy was more frequently observed in patients achieving stable disease or progressive disease than in patients achieving partial response (P=0.026). Patients with elevated PD-L1 expression on TC after neoadjuvant chemotherapy showed a trend to have a shorter progression-free survival than patients without elevated PD-L1 expression on TC, although the difference was not statistically significant in multivariate analysis (hazard ratio=2.38, 95% confidence interval=0.99–5.73, P=0.053). PD-L1 expression can be elevated by chemotherapy in lung cancer. Furthermore, elevation of PD-L1 expression on TC after neoadjuvant chemotherapy was associated with reduced chemotherapy response and inferior progression-free survival in patients with lung cancer. Lippincott Williams & Wilkins 2019 2019-05-28 /pmc/articles/PMC6587215/ /pubmed/31145232 http://dx.doi.org/10.1097/CJI.0000000000000275 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Clinical Studies Guo, Lei Song, Peng Xue, Xuemin Guo, Changyuan Han, Liankui Fang, Qing Ying, Jianming Gao, Shugeng Li, Wenbin Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer |
title | Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer |
title_full | Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer |
title_fullStr | Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer |
title_full_unstemmed | Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer |
title_short | Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer |
title_sort | variation of programmed death ligand 1 expression after platinum-based neoadjuvant chemotherapy in lung cancer |
topic | Clinical Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587215/ https://www.ncbi.nlm.nih.gov/pubmed/31145232 http://dx.doi.org/10.1097/CJI.0000000000000275 |
work_keys_str_mv | AT guolei variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer AT songpeng variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer AT xuexuemin variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer AT guochangyuan variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer AT hanliankui variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer AT fangqing variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer AT yingjianming variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer AT gaoshugeng variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer AT liwenbin variationofprogrammeddeathligand1expressionafterplatinumbasedneoadjuvantchemotherapyinlungcancer |